Abstract
The miniaturization of potentiometric sensors is developing only slowly. ISFET technology has not yet brought great breakthroughs in this respect. Potentiometric microelectrode arrays are developed however for DNA analysis. As potentiometry moves into new and unexpected applications such as biomolecules, multiply charged molecules, DNA, marker proteins, viruses and bacteria, dissolution testing..., the need for miniaturized sensors and arrays will grow. Possibly, planar screen printed electrodes can be applied. Use of the electrodes in hydrodynamic conditions may be needed. The use of FIA and HPLC for rapid screening of electrode compositions is explained. This provides new insights into these chemically dynamic sensor systems, and into the interaction of organic ionic molecules with surfaces.
Current Pharmaceutical Analysis
Title: Potentiometric Sensors for Organic Analytes: Insights to Proceed to Miniaturization
Volume: 5 Issue: 2
Author(s): Luc J. Nagels, Bert Vissers, Hugo Bohets, Joseph Everaert and Johan Robbens
Affiliation:
Abstract: The miniaturization of potentiometric sensors is developing only slowly. ISFET technology has not yet brought great breakthroughs in this respect. Potentiometric microelectrode arrays are developed however for DNA analysis. As potentiometry moves into new and unexpected applications such as biomolecules, multiply charged molecules, DNA, marker proteins, viruses and bacteria, dissolution testing..., the need for miniaturized sensors and arrays will grow. Possibly, planar screen printed electrodes can be applied. Use of the electrodes in hydrodynamic conditions may be needed. The use of FIA and HPLC for rapid screening of electrode compositions is explained. This provides new insights into these chemically dynamic sensor systems, and into the interaction of organic ionic molecules with surfaces.
Export Options
About this article
Cite this article as:
Nagels J. Luc, Vissers Bert, Bohets Hugo, Everaert Joseph and Robbens Johan, Potentiometric Sensors for Organic Analytes: Insights to Proceed to Miniaturization, Current Pharmaceutical Analysis 2009; 5(2) . https://dx.doi.org/10.2174/157341209788172898
DOI https://dx.doi.org/10.2174/157341209788172898 |
Print ISSN 1573-4129 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-676X |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Chronic Progressive Multiple Sclerosis – Pathogenesis of Neurodegeneration and Therapeutic Strategies
Current Neuropharmacology Molecules of Infectious Agents as Immunomodulatory Drugs
Current Topics in Medicinal Chemistry The Non-Canonical IκB Kinases IKKε and TBK1 as Potential Targets for the Development of Novel Therapeutic Drugs
Current Molecular Medicine Peripheral Blood Mononuclear Cells of Alzheimer's Disease Patients Control CCL4 and CXCL10 Levels in a Human Blood Brain Barrier Model
Current Alzheimer Research Arboviral Encephalitis and RNAi Treatment
Central Nervous System Agents in Medicinal Chemistry Anti-NMDA Receptor Encephalitis, Vaccination and Virus
Current Pharmaceutical Design Glycoconjugates: Roles in Neural Diseases Caused by Exogenous Pathogens
CNS & Neurological Disorders - Drug Targets Tandem Repeat Peptide Strategy for the Design of Neurotrophic Factor Mimetics
CNS & Neurological Disorders - Drug Targets The Amyloid Cascade Hypothesis in Alzheimer’s Disease: It’s Time to Change Our Mind
Current Neuropharmacology Molecular Approach to Targeted Therapy for Multiple Sclerosis
CNS & Neurological Disorders - Drug Targets Patent Annotations
Recent Patents on Anti-Infective Drug Discovery Viral Vectors for Gene-Directed Enzyme Prodrug Therapy
Current Gene Therapy EPO Relies upon Novel Signaling of Wnt1 that Requires Akt1, FoxO3a,GSK-3β, and β-Catenin to Foster Vascular Integrity during Experimental Diabetes
Current Neurovascular Research Endocannabinoids in Neuroimmunology and Stress
Current Drug Targets - CNS & Neurological Disorders How to Manage the Infectious Risk under Anti-TNF in Inflammatory Bowel Disease
Current Drug Targets Catatonia: A Brief Update
Current Psychiatry Reviews Development and Production of Commercial Therapeutic Monoclonal Antibodies in Mammalian Cell Expression Systems: An Overview of the Current Upstream Technologies
Current Pharmaceutical Biotechnology Anti-Viral
Current Bioactive Compounds Are B Cells a Potential Target for Therapeutic Intervention in the Classical T Cell-Mediated Autoimmune Disease Type 1 Diabetes?
Inflammation & Allergy - Drug Targets (Discontinued) Promises of Nanotechnology for Drug Delivery to Brain in Neurodegenerative Diseases
Current Nanoscience